Selectivity of direct plasma treatment and plasma-conditioned media in bone cancer cell lines.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
01 09 2021
01 09 2021
Historique:
received:
17
05
2021
accepted:
10
08
2021
entrez:
2
9
2021
pubmed:
3
9
2021
medline:
10
11
2021
Statut:
epublish
Résumé
Atmospheric pressure plasma jets have been shown to impact several cancer cell lines, both in vitro and in vivo. These effects are based on the biochemistry of the reactive oxygen and nitrogen species generated by plasmas in physiological liquids, referred to as plasma-conditioned liquids. Plasma-conditioned media are efficient in the generation of reactive species, inducing selective cancer cell death. However, the concentration of reactive species generated by plasma in the cell culture media of different cell types can be highly variable, complicating the ability to draw precise conclusions due to the differential sensitivity of different cells to reactive species. Here, we compared the effects of direct and indirect plasma treatment on non-malignant bone cells (hOBs and hMSCs) and bone cancer cells (SaOs-2s and MG63s) by treating the cells directly or exposing them to previously treated cell culture medium. Biological effects were correlated with the concentrations of reactive species generated in the liquid. A linear increase in reactive species in the cell culture medium was observed with increased plasma treatment time independent of the volume treated. Values up to 700 µM for H
Identifiants
pubmed: 34471164
doi: 10.1038/s41598-021-96857-9
pii: 10.1038/s41598-021-96857-9
pmc: PMC8410816
doi:
Substances chimiques
Culture Media, Conditioned
0
Plasma Gases
0
Reactive Oxygen Species
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
17521Informations de copyright
© 2021. The Author(s).
Références
Methods Enzymol. 2008;440:361-80
pubmed: 18423230
Free Radic Biol Med. 2015 Feb;79:28-44
pubmed: 25433364
Cancers (Basel). 2020 Jan 17;12(1):
pubmed: 31963398
Cancers (Basel). 2019 Sep 01;11(9):
pubmed: 31480642
Clin Cancer Res. 2007 Feb 1;13(3):789-94
pubmed: 17289868
Tumour Biol. 2016 Jun;37(6):7021-31
pubmed: 26888782
Cancers (Basel). 2021 Jan 25;13(3):
pubmed: 33504064
Trends Biotechnol. 2018 Jun;36(6):586-593
pubmed: 28755977
Oncotarget. 2017 Feb 28;8(9):15977-15995
pubmed: 27845910
Sci Rep. 2012;2:636
pubmed: 22957140
ACS Appl Mater Interfaces. 2020 Oct 21;12(42):47256-47269
pubmed: 33021783
Anticancer Res. 2016 Nov;36(11):5915-5922
pubmed: 27793916
Anticancer Res. 2020 Feb;40(2):841-846
pubmed: 32014927
Anticancer Res. 2017 Mar;37(3):1031-1038
pubmed: 28314261
Ther Adv Med Oncol. 2018 Jul 20;10:1758835918786475
pubmed: 30046358
Anticancer Res. 2019 Jan;39(1):151-157
pubmed: 30591452
Free Radic Biol Med. 2010 Jun 1;48(11):1485-91
pubmed: 20188819
Int J Mol Sci. 2020 Jun 23;21(12):
pubmed: 32585948
Sci Rep. 2016 Nov 08;6:36282
pubmed: 27824103
Int J Mol Sci. 2017 Sep 19;18(9):
pubmed: 28925941
Oncotarget. 2016 Apr 12;7(15):19910-27
pubmed: 26942565
Clin Chim Acta. 1998 Jun 22;274(2):177-88
pubmed: 9694586
Free Radic Biol Med. 2017 Sep;110:72-80
pubmed: 28571751
Anal Biochem. 1982 Oct;126(1):131-8
pubmed: 7181105
Nat Rev Drug Discov. 2009 Jul;8(7):579-91
pubmed: 19478820
Ann Surg Oncol. 2018 Jan;25(1):299-307
pubmed: 29139022
IEEE Trans Radiat Plasma Med Sci. 2017 Oct 11;2(2):121-128
pubmed: 30450481
Cancer Cell. 2006 Sep;10(3):175-6
pubmed: 16959608
Sci Rep. 2017 Nov 28;7(1):16478
pubmed: 29184131
Anticancer Agents Med Chem. 2018;18(6):769-775
pubmed: 28762318
Cancers (Basel). 2020 Jan 16;12(1):
pubmed: 31963132
Sci Rep. 2019 Jul 23;9(1):10681
pubmed: 31337843
Anticancer Res. 2017 Oct;37(10):5407-5414
pubmed: 28982850
Sci Rep. 2016 Jul 01;6:29098
pubmed: 27364563
Br J Cancer. 2011 Oct 25;105(9):1295-301
pubmed: 21979421
J Clin Biochem Nutr. 2017 Jan;60(1):33-38
pubmed: 28163380
Biointerphases. 2015 Jun 06;10(2):029518
pubmed: 25947392